Literature DB >> 34244902

Progression of Functional Gait in Hereditary Spastic Paraplegias.

Diana Maria Cubillos-Arcila1,2, Gustavo Dariva Machado3, Lauren Sehnem3, Daniela Burguêz3, Ana Paula Janner Zanardi4, Valéria Feijó Martins4, Leonardo Alexandre Peyré-Tartaruga2,4, Jonas Alex Morales Saute5,6,7,8,9.   

Abstract

Hereditary spastic paraplegias (HSP) are characterized by progressive deterioration of axonal projections of upper motor neurons leading to abnormal locomotion. The clinical course of HSP as well as the definition of the best instruments to assess its progression is largely unknown. The aim of this study was to investigate the progression of functional gait in individuals with HSP and to define sensitivity to change, minimal clinically important difference (MCID), and validity of timed functional tests of gait (TFT). The study was constituted of two phases: a cross-sectional study and a prospective cohort of 18 months. Twenty-five patients (17 being SPG4), and twenty-five age- and sex-matched control individuals performed TFT. Spastic paraplegia rating scale (SPRS), ten-meter walking test (10MWT), timed up and go test (TUG), both at self-selected and maximal walking speeds, and six-minute walking test (6MWT) were performed on baseline in both groups and after 18 months of follow-up only in the HSP cohort. In the cross-sectional analysis, all TFTs performances were greatly impaired in HSP patients compared to controls. After 18 months of follow-up, TFTs did not differ significantly from baseline in the statistical analysis, with some tests showing more frequent improvement than worsening. We have provided effect size measures and MCID for the evaluated instruments. HSPs clearly compromised TFTs performances, which were valid instruments for assessing disease severity. However, TFTs and SPRS did not capture the very slow motor evolution of HSPs, reinforcing the necessity of additional biomarkers of disease progression.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gait analysis; Genetic diseases; Hereditary spastic paraplegias; Natural history; Spasticity; Walking speed

Mesh:

Year:  2021        PMID: 34244902     DOI: 10.1007/s12311-021-01302-2

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  11 in total

1.  Disease severity affects quality of life of hereditary spastic paraplegia patients.

Authors:  S Klimpe; R Schüle; J Kassubek; S Otto; Z Kohl; S Klebe; T Klopstock; S Ratzka; K Karle; L Schöls
Journal:  Eur J Neurol       Date:  2011-06-01       Impact factor: 6.089

2.  Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia.

Authors:  Bas J H van Lith; Jasper den Boer; Bart P C van de Warrenburg; Vivian Weerdesteyn; Alexander C Geurts
Journal:  J Rehabil Med       Date:  2019-06-18       Impact factor: 2.912

3.  Objective assessment of gait after intrathecal baclofen in hereditary spastic paraplegia.

Authors:  S Klebe; H Stolze; F Kopper; D Lorenz; R Wenzelburger; G Deuschl; J Volkmann
Journal:  J Neurol       Date:  2005-03-14       Impact factor: 4.849

4.  The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity.

Authors:  R Schüle; T Holland-Letz; S Klimpe; J Kassubek; T Klopstock; V Mall; S Otto; B Winner; L Schöls
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

5.  Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients.

Authors:  Rebecca Schüle; Sarah Wiethoff; Peter Martus; Kathrin N Karle; Susanne Otto; Stephan Klebe; Sven Klimpe; Constanze Gallenmüller; Delia Kurzwelly; Dorothea Henkel; Florian Rimmele; Henning Stolze; Zacharias Kohl; Jan Kassubek; Thomas Klockgether; Stefan Vielhaber; Christoph Kamm; Thomas Klopstock; Peter Bauer; Stephan Züchner; Inga Liepelt-Scarfone; Ludger Schöls
Journal:  Ann Neurol       Date:  2016-03-11       Impact factor: 10.422

6.  The effect of hydrotherapy treatment on gait characteristics of hereditary spastic paraparesis patients.

Authors:  Yanxin Zhang; Richard Roxburgh; Liang Huang; John Parsons; T Claire Davies
Journal:  Gait Posture       Date:  2014-01-29       Impact factor: 2.840

Review 7.  Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches.

Authors:  Samuel Shribman; Evan Reid; Andrew H Crosby; Henry Houlden; Thomas T Warner
Journal:  Lancet Neurol       Date:  2019-07-31       Impact factor: 44.182

8.  Clinical and molecular characterization of hereditary spastic paraplegias: A next-generation sequencing panel approach.

Authors:  Daniela Burguez; Márcia Polese-Bonatto; Laís Alves Jacinto Scudeiro; Ingemar Björkhem; Ludger Schöls; Laura Bannach Jardim; Ursula Matte; Maria Luiza Saraiva-Pereira; Marina Siebert; Jonas Alex Morales Saute
Journal:  J Neurol Sci       Date:  2017-10-10       Impact factor: 3.181

9.  The timed "Up & Go": a test of basic functional mobility for frail elderly persons.

Authors:  D Podsiadlo; S Richardson
Journal:  J Am Geriatr Soc       Date:  1991-02       Impact factor: 5.562

10.  The extent of axonal loss in the long tracts in hereditary spastic paraplegia.

Authors:  G C Deluca; G C Ebers; M M Esiri
Journal:  Neuropathol Appl Neurobiol       Date:  2004-12       Impact factor: 8.090

View more
  1 in total

1.  Evoked potentials as biomarkers of hereditary spastic paraplegias: A case-control study.

Authors:  Samanta Ferraresi Brighente; Paul Vicuña; Ana Luiza Rodrigues Louzada; Gabriela Marchisio Giordani; Helena Fussiger; Marco Antonnio Rocha Dos Santos; Diana Maria Cubillos-Arcila; Pablo Brea Winckler; Jonas Alex Morales Saute
Journal:  PLoS One       Date:  2021-11-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.